# US 2026/0097023 A1 · Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097023 A1
- Document ID: US20260097023A1
- Status: Published application
- Kind: A1
- Application number: 19/405,788
- Filed: 2025-12-02
- Published: 2026-04-09
- Earliest claimed: 2020-07-15
- Assignees: Schabar Research Associates LLC
- Applicants: Schabar Research Associates LLC
- Inventors: Bernard SCHACHTEL
- Web page: https://patentgrep.com/patent/US20260097023A1

## CPC

- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/426: 1,3-Thiazoles
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are unit oral dose compositions that reduce the severity of heartburn and/or upset stomach or the risk of the occurrence of heartburn and/or upset stomach in a human in need of taking ibuprofen or the pharmaceutically acceptable salt thereof for the treatment of acute pain wherein the human is not experiencing heartburn and/or upset stomach prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen or the pharmaceutically acceptable salt thereof, wherein the amount of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine or the pharmaceutically acceptable salt thereof, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition in said human at the same specified time.

## Claims

### Claim 1

A method for reducing the severity of heartburn, upset stomach, or a combination thereof, in a human taking ibuprofen for the treatment of acute pain, the method comprising orally administering to the human a unit oral dose composition comprising (i) ibuprofen or a pharmaceutically acceptable salt thereof, wherein the amount of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine or a pharmaceutically acceptable salt thereof, wherein the amount of famotidine or a conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is from about 3 mg to about 20 mg per unit oral dose composition;
wherein the human is not experiencing heartburn, upset stomach, or a combination thereof prior to the oral administration of the unit oral dose composition, and
wherein the famotidine or a conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate that is about 10% to about 30% greater than the dissolution rate of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen at about 5 minutes, at about 10 minutes, at about 15 minutes, at about 20 minutes, at about 30 minutes, or at 45 minutes after administration of the unit oral dose composition to the human.

### Claim 2 (depends on 1)

The method of claim 1, wherein the unit oral dose composition comprises a core comprising ibuprofen or a pharmaceutically acceptable salt thereof surrounded by a layer comprising famotidine or the pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the layer of famotidine or the pharmaceutically acceptable salt thereof has a thickness of from about 10 μm to about 500 μm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the unit oral dose composition includes one or more barrier layers.

### Claim 5 (depends on 1)

The method of claim 1, wherein the unit oral dose composition includes a release-delaying agent.

### Claim 6 (depends on 1)

The method of claim 1, wherein the unit oral dose composition does not include a release-delaying agent.

### Claim 7 (depends on 1)

The method of claim 1, wherein the unit oral dose composition does not include an enteric coating, barrier layer, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the average particle size of ibuprofen or a pharmaceutically acceptable salt thereof is greater than the average particle size of famotidine or the pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein famotidine or the pharmaceutically acceptable salt thereof is in the form of microparticles, nanoparticles, or a combination thereof, wherein the average particle size of ibuprofen or a pharmaceutically acceptable salt thereof is greater than the average particle size of famotidine or the pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein famotidine or the pharmaceutically acceptable salt thereof and ibuprofen or a pharmaceutically acceptable salt thereof are in the form of microparticles, nanoparticles, or a combination thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the unit dose composition is a tablet having the shape of a disk, sphere, rhomboid, or oval or the unit dose composition is a caplet.

### Claim 12 (depends on 1)

The method of claim 1, wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate at about 10 minutes after administration of the unit oral dose composition to the human that is about 5 minutes to less than 10 minutes earlier than the time required for ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition to achieve the same dissolution rate after administration of the unit oral dose composition to the human.

### Claim 13 (depends on 1)

The method of claim 1, wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate at about 15 minutes after administration of the unit oral dose composition to the human that is about 5 minutes to about 10 minutes earlier than the time required for ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition to achieve the same dissolution rate after administration of the unit oral dose composition to the human.

### Claim 14 (depends on 1)

The method of claim 1, wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate at about 20 minutes after administration of the unit oral dose composition to the human that is about 5 minutes to about 15 minutes earlier than the time required for ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition to achieve the same dissolution rate after administration of the unit oral dose composition to the human.

### Claim 15 (depends on 1)

The method of claim 1, wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate at about 30 minutes after administration of the unit oral dose composition to the human that is about 5 minutes to about 25 minutes earlier than the time required for ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition to achieve the same dissolution rate after administration of the unit oral dose composition to the human.

### Claim 16 (depends on 1)

The method of claim 1, wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate at about 45 minutes after administration of the unit oral dose composition to the human that is about 5 minutes to about 40 minutes earlier than the time required for ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition to achieve the same dissolution rate after administration of the unit oral dose composition to the human.

### Claim 17 (depends on 1)

The method of claim 1, wherein the unit dose composition provides reduction of the severity of heartburn, upset stomach, or the combination thereof in the human when compared to the oral administration to the human of the same oral dosage of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the absence of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine.

### Claim 18 (depends on 1)

The method of claim 1, wherein the unit dose composition provides reduction of the severity of heartburn, upset stomach, or the combination thereof in the human when compared to the oral administration of the same oral dosage of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine following heartburn, upset stomach, or a combination thereof induced by the same oral dosage of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen administered to the human.

### Claim 19 (depends on 1)

The method of claim 1, wherein the acute pain comprises pain selected from the group consisting of inflammation, acute pain or stiffness of rheumatic or arthritic conditions arthritis flares, minor pain of arthritis, acute joint and body pains, acute muscular aches and strains, muscle soreness, dysmenorrhea, acute pain of ligamentous sprains, acute backache, minor aches and pains due to the common cold, sore throat, sinus pain, minor aches and pains due to fever, acute headache (tension-type or migraine), acute pain of minor surgery, acute pain of dental extractions, acute toothache, occasional sleeplessness when associated with minor aches and pains, and any combination thereof.

### Claim 20 (depends on 1)

The method of claim 1, wherein the unit oral dose composition with or without acetaminophen and/or diphenhydramine HCl or citrate provides enhanced acute pain reduction in the human when compared to the oral administration to the human of the same dosage of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the absence of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine.

### Claim 21 (depends on 1)

The method of claim 1, wherein the unit oral dose composition with or without acetaminophen and/or diphenhydramine HCl or citrate provides enhanced fever reduction in the human when compared to the administration to the human of the same dosage of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the absence of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine.

### Claim 22 (depends on 1)

The method of claim 1, wherein ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is from about 150 mg to about 400 mg per unit oral dose composition.

### Claim 23 (depends on 1)

The method of claim 1, wherein ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is about 200 mg per unit oral dose composition.

### Claim 24 (depends on 1)

The method of claim 1, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is about 10 mg per unit oral dose composition.

### Claim 25 (depends on 1)

The method of claim 1, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is about 20 mg per unit oral dose composition.

### Claim 26 (depends on 1)

The method of claim 1, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is from about 6.67 mg to about 13.33 mg per unit oral dose composition.

### Claim 27 (depends on 1)

The method of claim 1, wherein ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is from about 150 mg to about 400 mg per unit oral dose composition and famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is from about 3.33 mg to about 13.33 mg per unit oral dose composition.

### Claim 28 (depends on 1)

The method of claim 1, wherein ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is about 250 mg per unit oral dose composition and famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is from about 10 mg to about 13.33 mg per unit oral dose composition.

### Claim 29 (depends on 1)

The method of claim 1, wherein ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is from about 300 mg to about 400 mg per unit oral dose composition and famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is from about 10 mg to about 20 mg per unit oral dose composition.

### Claim 30 (depends on 1)

The method of claim 1, wherein the unit oral dose composition further comprises acetaminophen at a dosage of about 50 mg to about 500 mg.

### Claim 31 (depends on 1)

The method of claim 1, wherein ibuprofen or a pharmaceutically acceptable salt thereof is racemic.

### Claim 32 (depends on 1)

The method of claim 1, wherein ibuprofen or a pharmaceutically acceptable salt thereof is the S(+) enantiomer.

### Claim 33 (depends on 1)

The method of claim 1, wherein a pharmaceutically acceptable salt of ibuprofen is ibuprofen-amino acid.

### Claim 34 (depends on 1)

The method of claim 1, wherein the amino acid is one of lysine, arginine, or histidine.

### Claim 35 (depends on 1)

The method of claim 1, wherein a pharmaceutically acceptable salt of ibuprofen comprises at least one of ibuprofen-L-amino acid or ibuprofen-D-amino acid.

### Claim 36 (depends on 1)

The method of claim 1, wherein a pharmaceutically acceptable salt of ibuprofen comprises at least one of S(+)-ibuprofen-L-amino acid, S(+)-ibuprofen-D-amino acid, or S(+)-ibuprofen-DL-amino acid.

### Claim 37 (depends on 33)

The method of claim 33, wherein the L-amino acid comprises at least one of L-lysine, L-arginine or L-histidine, and the D-amino acid is selected from D-lysine, D-arginine or D-histidine.

### Claim 38 (depends on 1)

The method of claim 1, wherein a pharmaceutically acceptable salt of ibuprofen is IBU-X, where IBU is the conjugate base of ibuprofen and X comprises at least one of an alkali metal ion, an alkaline earth metal ion, or a substituted or unsubstituted ammonium ion.

### Claim 39 (depends on 1)

The method of claim 1, wherein the unit oral dose composition further comprises diphenhydramine or the conjugate acid of diphenhydramine in the pharmaceutically acceptable salt of diphenhydramine at a dosage of about 5 mg to about 50 mg.

### Claim 40 (depends on 1)

The method of claim 1, wherein the unit oral dose composition comprises a cellulose derivative.

### Claim 41 (depends on 40)

The method of claim 40, wherein the cellulose derivative comprises at least one of methyl oxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose succinate, cellulose acetate phthalate, methyl cellulose phthalate, methyl cellulose succinate, ethyl cellulose, ethylcarboxyethyl cellulose, carboxymethylethylcellulose glycerol monooctanoate, cellulose acetate succinate, or any combination thereof.

### Claim 42 (depends on 1)

The method of claim 1, wherein the unit oral dose composition comprises at least one of a copolymer of acrylic acid or an ester thereof and/or methacrylic acid or an ester thereof.

### Claim 43 (depends on 1)

The method of claim 1, wherein the unit oral dose composition comprises at least one of a copolymer formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate.

### Claim 44

A method for reducing the occurrence of heartburn, upset stomach, or a combination thereof in a human taking ibuprofen or a pharmaceutically acceptable salt thereof for the treatment of acute pain, the method comprising orally administering to the human a unit oral dose composition comprising (i) ibuprofen or a pharmaceutically acceptable salt thereof, wherein the amount of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine or a pharmaceutically acceptable salt thereof, wherein famotidine or a conjugate acid of famotidine of the pharmaceutically acceptable salt is at a dosage from about 3 mg to about 20 mg per unit oral dose composition;
wherein the human is not experiencing heartburn, upset stomach, or a combination thereof prior to the oral administration of the unit oral dose composition, and
wherein the famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition has a dissolution rate that is about 10% to about 30% greater than the dissolution rate of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen at about 5 minutes, at about 10 minutes, at about 15 minutes, at about 20 minutes, at about 30 minutes, or at 45 minutes after administration of the unit oral dose composition to the human.
